Quay Pharma to formulate capsules to be be administered in Redx’s trial
Quay Pharma will be formulating the capsules that will be administered in Redx’s trial.
Pharmaceuticals, Biotechnology and Life Sciences
Quay Pharma will be formulating the capsules that will be administered in Redx’s trial.
PureTech gets grant for third U.S. patent for methods of treating infectious and allergic diseases
Positive Phase III EXPAND study for Novartis
“Second quarter financial performance was in-line with expectations.” – Olivier Brandicourt, Sanofi CEO
Faron and Abzena in cancer medicine Clevegen manufacture deal
Vernalis has today announced the completion of the CCP-08 pivotal multiple-dose comparative bioavailability study.
Allergy Therapeutics Acarovac Plus one year study published
PureTech Health has introduced new members to its Scientific Advisory Board
English Court to consider Premaitha’s defence after hearing scheduled for July 2017
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.